Evaluation of Fructose Ingestion and the Renin Angiotensin System in Humans
NCT ID: NCT01407627
Last Updated: 2022-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
64 participants
INTERVENTIONAL
2011-07-31
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Animal studies show a strong link between excessive ingestion of fructose and the development of kidney and cardiovascular disease mediated by the renin angiotensin system, a hormonal system whose activation is detrimental to both the kidney and the heart. There has been very little research done on the potentially pathophysiological relationship between a high fructose diet and kidney and cardiovascular disease in humans.
The investigators hypothesize that ingestion of fructose will result in upregulation of the renin angiotensin system in humans.
Cardiovascular disease in women is a significant risk factor. By having women participate who are on the birth control pill and as well as women who use non oral forms of birth control or no birth control, kidney function and cardiovascular health can be examined as it relates to in the influence oral hormones might play. How the kidney responds to the influence of sugar and fructose while a woman is on an oral birth control pill, may reveal mechanisms that could help us understand cardiovascular disease in women.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diet and Systemic Inflammation
NCT01424306
Meta-analyses of Fructose and Cardiometabolic Risk
NCT01363791
Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease
NCT01608620
Fructose Rich Diet and Endothelial Function
NCT03939130
Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors
NCT02716870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. The renal and mean arterial pressure (MAP) response to an AngII challenge.
2. Reactive changes in circulating levels of renin and aldosterone with graded AngII challenge.
PRIMARY HYPOTHESES: Ingestion of fructose in healthy subjects will result in:
1. A decrease in renal and systemic sensitivity to infused AngII.
2. A decrease in the reactive changes in renin and aldosterone with graded AngII challenge.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fructose First
1. Study Day 1 - measurement of renal hemodynamics and blood pressure
2. Subjects will ingest fructose 200g daily x 14d
3. Study Day 2 - measurement of renal hemodynamics
4. Minimum 1 week "washout" period
5. Subjects will ingest dextrose 200g daily x 14d
6. Study Day 3 - measurement of renal hemodynamics and blood pressure
Fructose
Subjects will be randomized to one of 2 sequences:
Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Dextrose First
1. Study Day 1 - measurement of renal hemodynamics and blood pressure
2. Subjects will ingest dextrose 200g daily x 14d
3. Study Day 2 - measurement of renal hemodynamics
4. Minimum 1 week "washout" period
5. Subjects will ingest fructose 200g daily x 14d
6. Study Day 3 - measurement of renal hemodynamics and blood pressure
Fructose
Subjects will be randomized to one of 2 sequences:
Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fructose
Subjects will be randomized to one of 2 sequences:
Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to comprehend study and comply with high-salt diet
* kidney disease (on the approval of their nephrologist)
* on an oral birth control pill and non oral birth control and those not on birth control
Exclusion Criteria
* cerebrovascular disease (transient ischemic attacks or stroke)
* hypertension (BP\>140/90 or use of antihypertensive medications)
* diabetes mellitus (defined by history, use of hypoglycemic agents or a fasting glucose \>7mmol/L)
* hyperlipidemia (LDL \>4.5mmol/L or use of lipid-lowering agents)
* pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sofia Ahmed
Dr. Sofia Ahmed
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sofia B Ahmed, MD MMSc
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AIHS
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
University of Calgary
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
UCalgary Sugar Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.